ENGN Company Profile and Key Details

ENGN has shown mixed momentum, gaining 9.64% over the past week and -2.67% over the past quarter, though year-to-date performance is up 0.78%. Short-term trend indicators are bearishly aligned (SMA20 1.73%, SMA50 6.13%, SMA200 55.16%). The stock’s 14-day RSI is 52.54 (neutral), while the ATR of 0.71 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.12% below its high and over 278.49% above its low. Average 10-day trading volume of 158.21 thousand shares is below the 3-month average of 305.46 thousand, indicating normal recent market interest.

enGene Holdings Inc. has 51.11 million shares outstanding. The public float is 18.85 million shares, elevated short interest at 0.02% of float. This equals 10.08 thousand shares. The short ratio is 0.11 days. Institutional investors hold 103.89% of the float. Insiders own 13.63%.

enGene Holdings Inc. generated EPS of -$2.29 over the past year. Five-year average earnings growth is -255.92%. Wall Street analysts project EPS growth of 9.16% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $10.00. The high target offers 291.71% upside. The low target suggests 15.21% downside. The mean target is $23.50. This offers 170.74% upside. enGene Holdings Inc. earnings surprise history is a mixed track record. The quarter that ended December 22, 2025, missed forecasts by 32.73%. The prior quarter beat by 12.12%. Over the last six quarters, Apple has recorded several small beats. These include -13.51% in September 10, 2024.

enGene Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

enGene Holdings Inc. (NASDAQ:ENGN) closed at $7.05 USD, losing -$1.63 (-18.78%) from the previous close of $8.68. The stock is currently mid-range between its 52-week high and low $2.65 and $12.25. With a market capitalization of about $360.92 million, enGene Holdings Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.28). Key stats such as the average daily volume over the past year has been around 314.30 thousand shares, trading with heavier-than-usual volume. Headquartered in Saint-Laurent, None, enGene Holdings Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ronald H. W. Cooper, the company employs approximately 56 people and listed since February 01, 2022. enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

enGene Holdings Inc. (NASDAQ:ENGN) shares are flat 0.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows enGene Holdings Inc. trading at a premium to the broader market with a P/E of -43.94. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.63, suggesting 160.71% upside. Our AI forecast model points to short-term strength (0.81% over two weeks), a medium-term fall (-16.01% over three months), and a longer-term gain (107.03% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that enGene Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.81%, with price expected at $8.75 by March 20, 2026, within a range of $7.90 to $9.60 3-Month Outlook: Projected fall of -16.01%, reaching $7.29 by June 04, 2026, with a range of $6.64 to $7.82. 1-Year Outlook: Projected gain of 107.03%, with price at $17.97 by March 05, 2027, within a range of $5.20 to $27.84.

enGene Holdings Inc. trades at a P/E ratio of -43.94, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.76 suggesting the stock is closer to book value. The P/FCF stands at -3.64, also above market averages.